CompletedNot applicableNCT01328873

FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates

Pulmonary infiltrates frequently complicate the care of hematopoietic stem cell transplant (HSCT) and leukemia patients. Bronchoalveolar lavage (BAL) is frequently used to evaluate new pulmonary infiltrates in this population, however utility is limited by a historically low diagnostic yield for infection. In an effort to improve diagnostic yields, this study will complete a Fiberoptic Bronchoscopy (FOB) within 8 hours of radiographic documentation of pulmonary infiltrates, prior to initiating new antibiotic therapy. To further improve detection of microbiological pathogens, the study will utilize PCR testing with rapid turnaround time to detect atypical pneumonia (M pneumoniae, C. Pneumonia, Legionella species, and respiratory viruses) and aspergillosis.

Checked against the public recordLast updated Jul 11, 2017 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorNorthside Hospital, Inc.
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Northside Hospital, Inc.
Interventions being studied
Other: Microbiological analysis
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Autologous or allogeneic stem cell patients with new acute respiratory symptoms or pulmonary infiltrates * leukemia patients with new acute respiratory symptoms or pulmonary infiltrates thought to be unrelated to disease Exclusion Criteria: * Patients unwilling to undergo FOB * Patients unable to undergo FOB due to clinical status * Patients unable to undergo FOB within 8 hours of radiographic report of pneumonia * Patients unable to wait until completion of FOB to implement antibiotic changes * Adults unable to provide informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Northside HospitalAtlanta, Georgia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 11, 2017. Always confirm current availability with the study team.

View original record ↗